The goal of this Program Project is to develop novel vaccination strategies for oral carcinoma. It consists of four research projects, three cores and three clinical trials, with a plan to introduce peptide derived from human oral carcinomas and modified dendrite cells (DC) as vaccines in additional trials in subsequent years. Cancer of the oral cavity has one of the lowest five-year survival rates among all cancers. Improvements in survival of patients with oral carcinoma are most likely to come from the development of novel approaches to therapy and more effective strategies to prevent the development of primaries in individuals at high risk of oral squamous cell carcinoma (OSCC) and to eliminate recurrence or development of second primary cancers in patients with OSCC initially treated with conventional therapy. To meet the existing need for novel therapies in OSCC, the proposed Program will foster translational research aimed at advancing basic findings in the biology of OSCC to clinical trials. To meet these objectives, the Program Project is designed to bring together basic and clinical investigators with an interest in oral cancer in order to develop and evaluate effectiveness of vaccines that are expected to prevent primary oral cancer, its recurrence or appearance of second primary tumors. Research efforts will include identification and characterization of new immunologic peptides derived from OSCC, evaluation of synthetic p53- derived peptides and autologous DC for the ability to induce cytotolytic T lymphocyte (CTL responses), and examination of the role of the cytokine, IL-12, in modulation of anti-OSCC responses. Immunosuppression, which is common is patients with OSCC, will be studied at the level of signalling molecules, and possibilities for its reversal will be explored. Therapeutic goals include preclinical and clinical evaluations of vaccines with OSCC-derived peptides and HLA-matched DC, wild type p53 gene replacement theory, and studies with the cytokine, IL-12, to promote TH1 antitumor response. Complementary clinical trials with systemic IL-12 or with IL-12 gene therapy will be performed. Administrative, tissue procurement/DC laboratory and clinical support/biostatistics cores will support this basic and clinical vaccination program. The proposed novel immunologic approaches to therapy of OSCC are based on recent progress in DC biology, improved knowledge about antigen processing and delineation of defects in immune reactivity. This Program Project has a long-term objective of improving survival of OSCC patients through vaccination strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Program Projects (P01)
Project #
5P01DE012321-04
Application #
6176146
Study Section
Special Emphasis Panel (ZDE1-GH (17))
Program Officer
Sandberg, Ann
Project Start
1997-09-01
Project End
2002-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
4
Fiscal Year
2000
Total Cost
$801,575
Indirect Cost
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Whiteside, Theresa L; Ferris, Robert L; Szczepanski, Miroslaw et al. (2016) Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma. Head Neck 38 Suppl 1:E494-501
Visus, Carmen; Ito, Diasuke; Dhir, Rajiv et al. (2011) Identification of Hydroxysteroid (17?) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas. Cancer Immunol Immunother 60:919-29
Hoffmann, Thomas K; Trellakis, Sokratis; Okulicz, Kornelia et al. (2011) Cyclin B1 expression and p53 status in squamous cell carcinomas of the head and neck. Anticancer Res 31:3151-7
Visus, Carmen; Wang, Yangyang; Lozano-Leon, Antonio et al. (2011) Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8? T cells. Clin Cancer Res 17:6174-84
Mandapathil, Magis; Hilldorfer, Benedict; Szczepanski, Miroslaw J et al. (2010) Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 285:7176-86
Andrade Filho, Pedro A; Ito, Daisuke; Deleo, Albert B et al. (2010) CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 59:1561-8
Czystowska, Malgorzata; Strauss, Laura; Bergmann, Christoph et al. (2010) Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med (Berl) 88:577-88
Macatangay, Bernard J C; Szajnik, Marta E; Whiteside, Theresa L et al. (2010) Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One 5:e9852
Albers, Andreas E; Schaefer, Carsten; Visus, Carmen et al. (2009) Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer. Head Neck 31:773-81
Chikamatsu, Kazuaki; Sakakura, Koichi; Takahashi, Goro et al. (2009) CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer. Cancer Immunol Immunother 58:1441-8

Showing the most recent 10 out of 94 publications